BRKR Stock Recent News

Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.

Bruker faces significant headwinds due to NIH funding cuts, heavy reliance on academia, and declining financial performance versus peers. Despite operational challenges and a sharp drop in valuation, Bruker's NMR technology moat and long-term potential remain intact. I'm accumulating shares gradually at these low valuations, confident in mean reversion and management's ability to consolidate acquisitions.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop.

BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.

Explore Bruker's (BRKR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

ETTLINGEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the signing of multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year-to-date in 2025, supporting customers in the aviation security and defense industry to enhance threat detection capabilities. The contracts i.

Bruker Corporation BRKR reported worse-than-expected second-quarter financial results and cut its FY25 guidance on Monday.

Bruker Corporation BRKR is currently in the 17th phase of its 18-phase Adhishthana cycle on the weekly chart and signals point to potential trouble ahead. While several large financial institutions remain bullish, our analysis under the Adhishthana Principles suggests a far more cautious stance.

Bruker Corporation (NASDAQ:BRKR ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Frank H. Laukien - Chairman, CEO & President Gerald N.

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.